Catch pre-market movers with AI signals.
KALV(Quitar la ciudad)
KalVista (KALV) Stock Statistics, Valuation & Financial Metrics
Total Valuation
KalVista market cap is -- and enterprise value is --.
Share Statistics
KalVista has 53.24M shares outstanding, with a free float of 43.18M.
Valuation Ratios
KalVista's PE ratio is --, PB ratio is --, and PS ratio is --, showing whether the stock looks expensive or cheap.
Liquidity
KalVista's current ratio is 5.37, quick ratio is 5.37, and cash ratio is 4.99, showing its short-term liquidity position.
Return on Capital
KalVista's ROE is -190.18%, ROA is -97.71%, and ROIC is -195.08%, showing its return on capital profile.
Profitability
KalVista gross margin is --, operating margin is --, and net margin is --.
Operating Efficiency
KalVista's asset turnover is --, inventory turnover is --, and receivables turnover is --, indicating its operating efficiency.
Income Statement
KalVista's revenue is --, gross profit is --, net income is -203.10M, and EBITDA is -201.81M.
Balance Sheet
KalVista's total debt is 0, net debt is 0, total equity is 40.79M, and cash is 191.47M.
Cash Flow Statement
KalVista's operating cash flow is -167.19M, free cash flow is -167.97M, and CapEx is -786.00K.
Dividends & Yields
KalVista dividend yield is --, with a payout ratio of -- and dividend per share of --.
Analyst Rating
KalVista's latest analyst rating is Unrate, with an analyst target price of --.
Company Info
A developer of protease inhibitors for the treatment of hereditary angioedema, and diabetic macular edema
Per Share Metrics
KalVista's EPS is -3.94, book value per share is 0.81, and free cash flow per share is -3.25.
